Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B
References (20)
- et al.
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Biochem. Biophys. Res. Commun.
(1984) - et al.
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
European J. Pharmacol.
(1984) - et al.
Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase
- et al.
Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats
Neurosci. Lett.
(1985) - et al.
1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture
Neurosci. Lett.
(1985) - et al.
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
Life Sci.
(1985) - et al.
Deprenyl leads to prolongation of 1-dopa efficacy in Parkinson's disease
- et al.
A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N- N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- et al.
Tyramine antagonistic properties of AGN 1135; an irreversible inhibitor of monoamine oxidase type B
Br. J. Pharmacol.
(1981) - et al.
Modification of blood pressure and nictitating membrane response to sympathomimetic amines by selective monoamine oxidase inhibitors, type A and type B
Br. J. Pharmacol.
(1985)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 1985 Published by Elsevier B.V.